GI
GILD.US Gilead Sciences Inc
- Market cap
- USD 208B
- P/E
- -
- P/B
- 15.98x
- ROE
- -61.8%
- Dividend yield
- 1.92%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GILD.US undervalued?
Graham numberThe Graham number of Gilead Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gilead Sciences Inc fundamental analysis
No fundamental analysis for Gilead Sciences Inc yet.
Gilead Sciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus,…
Full company profileGilead Sciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Gilead Sciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 30.4B | 26.1B | 22.1B | 22.4B | 24.7B | 27.3B | 27.3B | 27.1B | 28.8B | 29.4B | 30.8B |
| Gross Profit | 26.1B | 21.7B | 17.3B | 17.8B | 20.1B | 20.7B | 21.6B | 27.1B | 22.5B | 23.2B | 24.6B |
| Operating Income | 17.6B | 14.1B | 8.20B | 4.29B | 4.07B | 9.92B | 7.33B | 7.61B | 1.66B | 11.7B | 11.6B |
| EBITDA | 19.2B | 15.9B | 10.3B | 7.56B | 4.13B | 11.3B | 8.85B | 7.61B | 4.43B | 13.6B | -2.30B |
| Net Income | 13.5B | 4.63B | 5.46B | 5.39B | 123M | 6.23B | 4.59B | 5.67B | 480M | 8.51B | -8.06B |
| EPS | 9.94 | 3.51 | 4.17 | 4.22 | 0.10 | 4.93 | 3.64 | 4.50 | 0.38 | 6.78 | -6.44 |
| Balance Sheet | |||||||||||
| Total Assets | 57.0B | 70.3B | 63.7B | 61.6B | 68.4B | 68.0B | 63.2B | 62.1B | 59.0B | 59.0B | 51.4B |
| Total Liabilities | 37.6B | 49.8B | 42.1B | 39.0B | 50.2B | 46.9B | 42.0B | 39.4B | 39.7B | 36.4B | 38.5B |
| Shareholders' Equity | 19.4B | 20.4B | 21.4B | 22.5B | 18.2B | 21.1B | 21.2B | 22.8B | 19.3B | 22.7B | 13.0B |
| Cash & Short-term Investments | 32.4B | 25.5B | 30.1B | 24.4B | 7.41B | 6.52B | 6.39B | 7.26B | 11.6B | 9.61B | 6.44B |
| Total Debt | 27.8B | 33.5B | 27.3B | 24.6B | 31.4B | 26.7B | 25.2B | 25.0B | 26.7B | 24.9B | 26.2B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 17.0B | 11.9B | 8.40B | 9.14B | 8.17B | 11.4B | 9.07B | 8.01B | 10.8B | 10.0B | 14.9B |
| Capital Expenditure | 748M | 590M | 924M | 825M | 650M | 579M | 728M | 585M | 523M | 563M | 659M |
| Free Cash Flow | 16.3B | 11.3B | 7.48B | 8.32B | 7.52B | 10.8B | 8.34B | 7.42B | 10.3B | 9.46B | 14.2B |
| Ratios | |||||||||||
| ROE | 69.7% | 22.6% | 25.5% | 23.9% | 0.7% | 29.5% | 21.6% | 24.8% | 2.5% | 37.5% | -61.8% |
| ROA | 23.7% | 6.6% | 8.6% | 8.7% | 0.2% | 9.2% | 7.3% | 9.1% | 0.8% | 14.4% | -15.7% |
| Net Profit Margin | 44.4% | 17.7% | 24.7% | 24.0% | 0.5% | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% | -26.2% |
| Debt to Equity | 1.43x | 1.64x | 1.28x | 1.09x | 1.73x | 1.27x | 1.19x | 1.09x | 1.38x | 1.10x | 2.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Gilead Sciences Inc dividends
- Dividend yield
- 1.92%
- Forward dividend
- 3.28 USD
- Payout ratio
- 47.0%
- Ex-dividend date
- Dec 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 4.00B | 3.19 | 47.0% |
| 2024 | USD 3.92B | 3.12 | 816.3% |
| 2023 | USD 3.81B | 3.03 | 67.2% |
| 2022 | USD 3.71B | 2.94 | 80.8% |
| 2021 | USD 3.61B | 2.86 | 57.9% |
| 2020 | USD 3.45B | 2.73 | 2,804.1% |
| 2019 | USD 3.22B | 2.52 | 59.8% |
| 2018 | USD 2.97B | 2.27 | 54.5% |
| 2017 | USD 2.73B | 2.07 | 59.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jan 28, 2013.
Who owns Gilead Sciences Inc
- Insiders 0.11%
- Institutions 91.33%
- Public & others 8.56%
- Shares outstanding 1.24B
- Free float 1.24B
Top funds holding GILD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 39.4M | 3.17% | -0.23% | Sep 2026 |
| Vanguard 500 Index Investor | 32.6M | 2.63% | -1.27% | Sep 2026 |
| Invesco QQQ Trust | 25.8M | 2.08% | -0.10% | Oct 2026 |
| iShares Core S&P 500 ETF | 16.5M | 1.33% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 16.1M | 1.30% | -0.01% | Sep 2026 |
| Dodge & Cox Stock I | 15.8M | 1.28% | -8.38% | Sep 2026 |
| American Funds Income Fd of Amer A | 15.5M | 1.25% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 15.1M | 1.22% | -0.25% | Oct 2026 |
| Vanguard MStar Value Index Investor | 11.8M | 0.95% | -0.47% | Sep 2026 |
| American Funds Washington Mutual A | 11.2M | 0.91% | -5.58% | Sep 2026 |
| American Funds Capital Inc Bldr A | 9.38M | 0.76% | +44.03% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 9.07M | 0.73% | +0.88% | Oct 2026 |
| Fidelity Contrafund | 7.10M | 0.57% | +5.53% | Sep 2026 |
| Vanguard Dividend Appreciation ETF | 7.02M | 0.57% | -0.18% | Sep 2026 |
| Vanguard Institutional Index I | 6.56M | 0.53% | -1.18% | Sep 2026 |
| JPMorgan Large Cap Growth I | 6.51M | 0.52% | -0.91% | Sep 2026 |
| American Funds American Balanced A | 6.36M | 0.51% | -33.98% | Sep 2026 |
| Vanguard Equity-Income Inv | 6.10M | 0.49% | -0.56% | Sep 2026 |
| iShares Biotechnology ETF | 6.01M | 0.48% | -0.36% | Oct 2026 |
| Invesco NASDAQ 100 ETF | 5.90M | 0.48% | +0.15% | Oct 2026 |
Top institutions holding GILD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 122M | 9.82% | +2.38% | Jun 2026 |
| Vanguard Capital Management, LLC | 81.1M | 6.54% | +0.54% | Jun 2026 |
| FMR Inc | 66.9M | 5.39% | -7.00% | Jun 2026 |
| State Street Corp | 61.2M | 4.94% | +2.27% | Jun 2026 |
| Capital World Investors | 41.0M | 3.30% | -0.71% | Jun 2026 |
| Amvescap Plc. | 39.8M | 3.21% | -4.24% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 35.3M | 2.85% | +0.53% | Jun 2026 |
| Geode Capital Management, LLC | 30.1M | 2.42% | +1.14% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 30.0M | 2.42% | +14.28% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 24.0M | 1.94% | +3.03% | Jun 2026 |
| Dodge & Cox | 23.7M | 1.91% | -2.36% | Jun 2026 |
| NORGES BANK | 22.0M | 1.77% | +3.01% | Jun 2026 |
| JPMorgan Chase & Co | 20.8M | 1.68% | -38.75% | Jun 2026 |
| Capital Research Global Investors | 19.4M | 1.56% | -28.51% | Jun 2026 |
| Bank of America Corp | 18.6M | 1.50% | -6.66% | Jun 2026 |
| Bank of New York Mellon Corp | 15.3M | 1.23% | +1.40% | Jun 2026 |
| Northern Trust Corp | 13.8M | 1.11% | +0.06% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 13.0M | 1.05% | -1.61% | Jun 2026 |
| Wellington Management Company LLP | 12.7M | 1.02% | -6.19% | Jun 2026 |
| The Goldman Sachs Group Inc | 10.8M | 0.87% | -2.59% | Jun 2026 |
Gilead Sciences Inc company profile
- Company name
- Gilead Sciences Inc
- Ticker
- GILD.US
- Exchange
- USA Stocks
- Listed since
- Jan 22, 1992
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17,000
- Fiscal year end
- December
- Address
- 333 Lakeside Drive, Foster City, CA, United States, 94404
- Phone
- 650 574 3000
- Website
- gilead.com
About Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
Gilead Sciences Inc management
10- Mr. Daniel Patrick O'DayChairman & CEO · born 1965
- Mr. Andrew D. DickinsonExecutive VP & CFO · born 1970
- Ms. Johanna MercierChief Commercial & Corporate Affairs Officer · born 1970
- Dr. Dietmar P. Berger M.D., Ph.D.Chief Medical Officer · born 1969
- Ms. Erin E. BurkhartSenior VP, Controller & Chief Accounting Officer · born 1979
- Ms. Jacquie Ross C.F.A.Senior Vice President of Treasury & Investor Relations
- Ms. Keeley M. Cain WettanExecutive VP, General Counsel of Legal & Compliance and Secretary · born 1975
- Ms. Jyoti K. MehraExecutive Vice President of Human Resources · born 1976
- Dr. Linda Slanec Higgins Ph.D.Senior Vice President of Research, Innovation & Portfolio · born 1962
- Dr. Flavius Martin M.D.Executive Vice President of Research